Introduction
============

Novel biological agents, including anti-epidermal growth factor receptor (EGFR), anti-VEGF targeting therapies, and small-molecule multikinase inhibitors, have recently changed the standard of care of metastatic colorectal cancer (mCRC) patients.[@R1]^,^[@R2] While the use of positive predictive biomarkers for biological therapy would be desirable in order to identify specific subsets of responsive patients, to date the only validated negative predictive biomarker for mCRC is the mutational status of all members of the *RAS* gene family, which identifies mCRC patients not eligible to monoclonal antibody (moAb) anti-EGFR therapies.[@R3]^,^[@R4] Emphasizing the limitations of negative predictive biomarkers, unfortunately only a subgroup of WT RAS mCRC patients respond to anti-EGFR drugs, being the molecular mechanism/s underlying resistance to anti-EGFR treatment not fully understood.[@R5] Activating mutations in other members of the RAS-BRAF-MEK and PI3K-AKT pathways, both acting downstream of the EGFR signaling cascade, are being investigated as further potential predictive biomarkers.[@R6]^-^[@R8]

Apparently, no specific target treatment seems to be available for WT RAS and anti-EGFR resistant mCRC patients. Indeed, the inhibition of the BRAF^V600E^ oncoprotein by the small-molecule drug vemurafenib, which is highly effective in melanoma,[@R9] showed a very limited response in the mCRC setting.[@R7]^,^[@R8] Coherently, only a prognostic significance has been attributed to BRAF mutations in CRC, so far.[@R7] Interestingly however, preclinical studies have indicated that EGFR reactivation contributes to insensitivity of BRAF-mutant CRC to vemurafenib. Thus, the association of BRAF and EGFR inhibitors might effectively target BRAF^V600E^ mutant colon cancers.[@R10]^,^[@R11] We report here the first case of a patient with *BRAF*-mutant, amplified *EGFR* (double positive) and *KRAS/PIK3CA* WT, not-amplified *HER2* (triple negative) mCRC whose disease had progressed on standard lines of treatment, but successfully responded to a new combination therapy consisting of vemurafenib (Zelboraf^TM^) and panitumumab (Vectibix^TM^).

Case Report
===========

A 55-y-old man was admitted to our oncology department in July 2007 for a poorly-differentiated adenocarcinoma of the transverse colon. Preoperative carcinoembryonic antigen (CEA) and CA19.9 serum levels were 1.2 ng/mL and 63 U/mL, respectively.

The tumor was completely removed by a right hemicolectomy with lymph node dissection. The patient was staged as IIIB and adjuvant standard treatment with FOLFOX4 (6 mo) was performed. Eleven months later, the patient developed peritoneal carcinomatosis and was treated with FOLFIRI-bevacizumab (9 cycles), discontinued for pulmonary embolism, followed by cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.

After a 12 mo disease-free interval, an increment of CA19.9 and a CT scan revealed a peritoneal progression. At this time the patient was characterized for wild-type KRAS mutational status and high EGFR expression by immunohistochemistry and underwent several lines of treatment, such as irinotecan--cetuximab, a second peritoneal cytoreductive surgery, capecitabine--bevacizumab, or sorafenib--panitumumab (off-label use). Every disease progression was exclusively peritoneal and marked by a significant increase in CA19.9 and CEA. An additional line of treatment with regorafenib demonstrated a good control of the disease for 9 mo in an expanded access program. Subsequently, the patient showed a significant rise in serum markers (CA19.9 and CEA) and a multivisceral disease progression (peritoneum, liver, and lung) accompanied by important clinical troubles including diffuse abdominal pain, weight loss, and episodes of sub-ileus.

In order to find additional treatment opportunities dictated by tumor biology, the molecular profile of the tumor was evaluated on a liver metastasis biopsy performed at the time of the latest progression and on previously collected tumor material (primary lesion and peritoneal implants). All samples concordantly revealed the following status: non-amplified *HER2*, *KRAS* WT, *PIK3CA* WT, amplified *EGFR*, and mutant *BRAF^V600E^*. Personalized medicine challenges the ethical issues related to off-label therapies and pharmacogenomics.[@R12]^,^[@R13] The lack of other established therapeutic alternatives together with the above mentioned molecular characterization and preclinical data, met the ethical constraints of a tailored therapy, and prompted us to propose a vemurafenib-panitumumab combined treatment. The protocol was approved by the institutional review board (Policlinico Umberto I, Sapienza University of Rome) on June 2013, and the patient provided written informed consent.

Patient restaging before vemurafenib--panitumumab treatment showed hepatic, pulmonary and peritoneal disease measurable at spiral CT scan ([Fig. 1A](#F1){ref-type="fig"}). CEA and CA19.9 serum levels were 558 ng/mL and 4800 U/mL, respectively ([Fig. 2](#F2){ref-type="fig"}). Q-PCR analysis of plasma DNA indicated the presence of circulating tumor DNA (ctDNA) via the identification of the *BRAF^V600E^* mutation ([Fig. 3](#F3){ref-type="fig"}).

![**Figure 1.** CT scans of the patient before and after panitumumab-vemurafenib treatment for metastatic CRC. Tumor masses (arrow) can be seen in the liver of the patient before initiation of panitumumab-vemurafenib treatment (**A**). The masses (arrow) became hypodense, homogenous and significantly reduced in size on CT obtained 3 and 6 mo after treatment (**B and C**), indicating good response to combination treatment.](cbt-15-826-g1){#F1}

![**Figure 2.** Trend of CEA and CA 19--9 during vemurafenib and panitumumab combination therapy.](cbt-15-826-g2){#F2}

![**Figure 3.** Detection of the BRAF^V600E^ mutation in patient\'s CRC tissue and plasma. (**A**) Electropherogram showing the heterozygous BRAF^V600E^ mutation in DNA isolated from patient\'s CRC tissue. (**B**) Allele-specific Q-PCR detection of the BRAF^V600E^ mutation in plasma free DNA reveals the presence of circulating tumor DNA before treatment (T0) but not 12 wk after treatment initiation (T1). Data are reported as averages of the threshold cycles (Ct) obtained in two different Q-PCR for the BRAF^V600E^ amplicon and the reference gene amplicon.](cbt-15-826-g3){#F3}

The patient was treated with panitumumab 6 mg/kg IV every 14 d and vemurafenib 960 mg orally twice daily. Soon after 4 wk, a significant clinical benefit with complete regression of the clinical symptoms occurred. Twelve weeks later, the programmed disease restaging with CT scan showed a strong reduction of all metastatic lesions (PR according to RECIST1.1 criteria) ([Fig. 1B](#F1){ref-type="fig"}). Consistent with the CT scan, tumor markers also showed a significant decrease: CEA, 51 ng/mL, CA19.9, 221 U/mL ([Fig. 2](#F2){ref-type="fig"}). Most importantly, ctDNA harboring the *BRAF^V600E^* mutation disappeared from plasma. To date, the patient is still asymptomatic 28 wk after starting the treatment when the CT scan showed a further reduction of all metastatic lesions (PR according to RECIST1.1 criteria) ([Fig. 1C](#F1){ref-type="fig"}). Tumor markers are stably low ([Fig. 2](#F2){ref-type="fig"}) and circulating *BRAF^V600E^* DNA absent. Treatment regimen is being well tolerated and the patient only presents minor skin-related toxicity (maximum grade 2). In particular no cutaneous toxicity (such as squamous cell carcinomas and keratoacanthomas) typically associated with vemurafenib are observed.

Discussion
==========

Our work represents the first clinical evidence that the combination of an inhibitor of BRAF^V600E^ (vemurafenib) and an EGFR antagonist (panitumumab) is well tolerated and results in a highly effective control of the disease, in a mCRC patient extensively pretreated with several standard and off-label lines of treatment.

*BRAF* belongs to a gene family also including *CRAF* (or *RAF1*) and *ARAF*, encoding serine--threonine kinases that heterodimerize each other and constitute, together with downstream MEK and ERK proteins, a powerful mitogen-activated protein kinase (MAPK) pathway. RAF kinases are activated by several receptor tyrosine kinases (RTKs) such as EGFR. Notably, while mutations of *ARAF* and *CRAF* are rare in human cancer, mutated *BRAF* frequently occurs in papillary thyroid carcinoma, melanoma, hairy cell leukemia, hepatocellular carcinoma, and 11% of CRC.[@R14] To this regard, BRAF^V600E^ is an ideal druggable target in BRAF mutated cancers (i.e., CRC) since it is active as a monomer in an upstream EGFR/RAS-independent way, thus providing an explanation to the observed resistance to inhibitors of EGFR/RAS pathway (i.e., anti-EGFR antibodies) ([Fig. 4](#F4){ref-type="fig"}, left panel). The resistance to EGFR-targeted therapies eventually developing along progression of lung, colorectal, pancreatic, or head and neck cancers, is challenging because of the various mechanisms underlying anti-EGFR insensitivity (summarized in [Fig. 4](#F4){ref-type="fig"}, right panel). Understanding these various resistance pathways would provide an opportunity to develop new inhibitors to prevent or overcome therapeutic resistance.[@R15] In this context, it can be predicted that BRAF^V600E^-containing CRCs would be inhibitable by BRAF^V600E^ antagonists ([Fig. 4](#F4){ref-type="fig"}, right panel). Nevertheless, BRAF^V600E^ CRCs fail to respond to mutated BRAF inhibitors as single agents.[@R8] Likewise a short-term sensitivity to anti-BRAF^V600E^ monotherapy has been reported in melanoma.[@R16]

![**Figure 4.** Model of BRAF^V600E^-dependent cell growth and mechanisms of resistance to BRAF inhibition and restoring of drug sensitivity through combination therapies. BRAF mutation confers constitutive pathway activation (red arrows) independent of upstream RTKs (EGFR, IGF-1R)/RAS signaling (left panel), providing an explanation to the observed insensitivity to anti-EGFR antibody treatment (panitumumab, cetuximab) in BRAF mutant CRC. Such a process is blunted by BRAF^V600E^ (BRAF^mut^) inhibitors (blue symbols and drugs) (right panel). Additional mechanisms of EGFR primary or secondary resistance described in lung, head-neck cancer and CRC (i.e., EGFR mutation; oncogenic shift or activation of a bypass pathway such as KRAS, BRAF, PIK3CA, secondary EGFR mutation or a parallel/alternative pathway \[PTEN, IGF1\] is also indicated). Right panel also illustrates how bypass and resistance to BRAF-inhibitors may occur through the rescue of the BRAF^V600E^-mediated attenuation of ERK negative feedback induced by BRAF inhibitors and subsequent reactivation of ligand-dependent signaling from EGFR or IGF-1R or via wild type RAS/RAF or *PIK3CA*/AKT or *PIK3CA* or EGFR or MEK1 or further BRAF gain-of-function mutations (*PIK3CA*^mut^ or asterisks) in several tumor types. Drugs under development in preclinical models or clinical trials to overcome BRAF inhibitor resistance are labeled in blue. References are quoted in the text.](cbt-15-826-g4){#F4}

Several mechanisms have been reported to underlie the resistance to BRAF inhibitors, as summarized in [Figure 4](#F4){ref-type="fig"}.[@R17]^,^[@R18] While inhibitors of mutant BRAF monomers suppress the ERK signaling, they relieve ERK-dependent negative feedback and reactivate ligand-dependent EGFR/RAS signaling upon wild-type RAF dimers in melanoma cells.[@R19] Likewise, recent preclinical evidence of the feedback reactivation of EGFR in CRC by vemurafenib-mediated blockade of BRAF has been reported[@R10]^,^[@R11] ([Fig. 4](#F4){ref-type="fig"}). In turn, this triggers sustained RAS- and CRAF-mediated MAPK signaling and cell proliferation. Blocking EGFR activity with a monoclonal antibody to EGFR has been shown to restore the sensitivity to vemurafenib in preclinical models,[@R10]^,^[@R11] providing a strong rationale for the combination of vemurafenib and anti-EGFR antibodies in BRAF-mutated CRC.

Resistance to BRAF inhibitors has also been reported through further activation of RAS/MAPK pathway (e.g., mutations of NRAS or MEK1, loss of NF1, alternatively spliced variants of BRAF, amplification of CRAF or BRAF) as well as activation of additional parallel signaling pathways such as the IGF1R/PI3K/AKT (e.g., resulting from PTEN loss) or PDGFRβ pathways[@R17]^,^[@R20]^-^[@R24] ([Fig. 4](#F4){ref-type="fig"}). Although this drug resistance mechanism and its overcoming by combined treatments is potentially operating in several other tumors harboring BRAF mutations, no clinical efficacy has been reported either.

In addition to the clinical efficacy of the combined therapy with vemurafenib and panitumumab described here, Al-Marrawi et al.[@R25] recently reported that treatment of a single patient with a combination of sorafenib and cetuximab led to a mixed radiographic response with some areas showing dramatic improvement and other areas showing stable disease over a 7-mo period. These findings are consistent with the modest disease control we also observed in our case treated with panitunumab and sorafenib. However, sorafenib, a multi-kinase inhibitor with limited activity on BRAF^V600E^, cannot be considered an optimal drug for the specific purpose. Indeed, weak inhibition of BRAF by sorafenib would transactivate RAF dimers maintaining a still consistent downstream MEK activity.[@R18]

Our case report raises several considerations that need to be exploited in subsequent studies performed on large series. The first one is related to the observation of BRAF mutation together with EGFR amplification, suggesting that vemurafenib might be an effective drug in BRAF mutant mCRC patients if used in association with EGFR inhibitors. This would blunt escaping signaling pathways (i.e., PI3K*-*AKT) downstream of the amplified EGFR responsible for the maintenance of the disease progression, suggesting that the dramatic response observed in our case might have been further influenced by EGFR amplification. Thus, a careful selection of the patients eligible to this treatment might be performed on the basis of two distinct positive predictive markers.

The second one is related to drugs adverse effects. Skin is largely the most frequent target of adverse events for both drugs. However, vemurafenib toxicity spectrum, (e.g., squamous cell carcinomas/keratoacanthomas, maculopapular rashes, hyperkeratosis) is significantly distinct from that of panitumumab (acneiform rash, paronychia, xerosis).[@R26] In the case described, no cutaneous toxic effects typically associated with vemurafenib were observed. In particular, squamoproliferative lesions appearing at early times (median time 8 wk) during vemurafenib treatment[@R27] were completely absent. Therefore the vemurafenib-panitumumab combination appears to limit the typical toxicity of single agents.

Besides overcoming BRAF inhibitor resistance through co-targeting activated parallel or upstream RTK mitogenic or survival pathways (i.e., EGFR, MET, IGF1R), additional therapeutic strategies include the combined use of MEK or ERK or AKT inhibitors[@R17]^,^[@R28]^,^[@R29] as well as the intermittent administration of BRAF inhibitors described in preclinical models.[@R30] However, to date no clinical evidence substantiates this hypothesis.

Conclusions and Future Directions
=================================

Here we report the first clinical evidence that the combination of an anti-EGFR (panitumumab) and an inhibitor of BRAF^V600E^ (vemurafenib) is well tolerated and results in a highly effective disease control in an extensively pretreated mCRC patient. The possibility to select patients eligible to this therapeutic approach on the basis of two distinct positive predictive markers (EGFR gene amplification/overexpression and mutant BRAF) and the apparent reciprocal limitation of the side effects of the two drugs are interesting hypotheses to be tested in prospective studies. Furthermore, unraveling the various mechanisms of resistance to BRAF inhibition is expected to pinpoint novel combination therapies. To this regard, recent advances in CRC patients classification based on gene expression profiles[@R31] may help identifying new strategies for personalized treatment.
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